Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236428 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT03236428: Active Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy, sponsored by Dana-Farber Cancer Institute.
NCT03236428 is a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 42 participants, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03236428, a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
Primary Outcome
To determine the proportion of patients who are in VGPR or better after twenty cycles of therapy with Daratumumab. This will be determined at the time of best overall response.
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
California
- Pacific Cancer Care - Monterey
Colorado
- Colorado Blood Cancer Institute - Denver
Michigan
- Karmanos Cancer Insitute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2026-10-04 |
| Phase | Phase 2 |
What the registry record for NCT03236428 still lists
NCT03236428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT03236428 lists 6 locations in 4 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT03236428 about?
NCT03236428 is a clinical study titled "Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma". This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
What is the current status of trial NCT03236428?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-11-24. Estimated completion is 2026-10-04.
What conditions does trial NCT03236428 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma, Monoclonal Gammopathy.
What interventions are being tested in trial NCT03236428?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT03236428?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03236428 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03236428's enrollment target sits among peer trials
42 16th of 20 higher than 5 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI